Orchestra BioMed (NASDAQ:OBIO) Stock Rating Reaffirmed as “Buy” by B. Riley Financial

Orchestra BioMed (NASDAQ:OBIO – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at B. Riley Financial in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $12.00 price objective on the stock, up from their previous price objective of $11.00. B. Riley Financial‘s target price indicates a potential upside of 73.26% from the stock’s current price.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright raised their target price on shares of Orchestra BioMed from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, November 13th. Weiss Ratings upgraded shares of Orchestra BioMed from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 10th. BTIG Research upped their price target on shares of Orchestra BioMed from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, November 13th. Chardan Capital reissued a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research note on Friday, October 23rd. Finally, Wall Street Zen upgraded shares of Orchestra BioMed from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $13.43.

View Our Latest Report on Orchestra BioMed

Orchestra BioMed Stock Performance

Shares of NASDAQ OBIO traded down $0.07 during trading on Friday, hitting $6.93. The company had a trading volume of 68,681 shares, compared to its average volume of 306,813. The stock has a 50 day simple moving average of $6.00 and a 200 day simple moving average of $4.69. The company has a debt-to-equity ratio of 4.58, a quick ratio of 7.24 and a current ratio of 7.25. Orchestra BioMed has a 12 month low of $3.46 and a 12 month high of $7.82. The firm has a market capitalization of $425.60 million, a P/E ratio of -9.17 and a beta of 0.56.

Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.10. The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.13 million. Orchestra BioMed had a negative return on equity of 186.93% and a negative net margin of 182.50%. As a group, analysts anticipate that Orchestra BioMed will post -1.43 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Darren Sherman sold 15,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $5.74, for a total transaction of $86,100.00. Following the completion of the sale, the insider owned 1,104,402 shares in the company, valued at approximately $6,339,267.48. This trade represents a 1.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David P. Hochman bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were acquired at an average cost of $4.79 per share, for a total transaction of $47,900.00. Following the purchase, the insider directly owned 1,070,746 shares in the company, valued at $5,128,873.34. This trade represents a 0.94% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 58,000 shares of company stock valued at $288,560 and have sold 45,000 shares valued at $255,600. Corporate insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Orchestra BioMed

A number of institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its position in shares of Orchestra BioMed by 112.8% during the third quarter. Goldman Sachs Group Inc. now owns 382,160 shares of the company’s stock valued at $2,377,000 after buying an additional 202,554 shares during the last quarter. Jump Financial LLC bought a new position in shares of Orchestra BioMed during the third quarter worth $136,000. Empowered Funds LLC bought a new position in shares of Orchestra BioMed during the third quarter worth $450,000. HighTower Advisors LLC grew its stake in Orchestra BioMed by 8.7% during the third quarter. HighTower Advisors LLC now owns 38,462 shares of the company’s stock valued at $239,000 after acquiring an additional 3,087 shares in the last quarter. Finally, Daytona Street Capital LLC grew its stake in Orchestra BioMed by 27.7% during the third quarter. Daytona Street Capital LLC now owns 123,148 shares of the company’s stock valued at $744,000 after acquiring an additional 26,750 shares in the last quarter. 53.20% of the stock is owned by hedge funds and other institutional investors.

About Orchestra BioMed

(Get Free Report)

Orchestra BioMed is a medical technology company that develops therapies for cardiovascular and other diseases, often in collaboration with established medical-device companies. Its work focuses on technologies intended to integrate with existing treatment approaches and devices. The company’s lead program, AVIM therapy, is designed to lower blood pressure in people with pacemakers by adjusting the timing of cardiac pacing. Orchestra BioMed is also developing Virtue SAB, a drug-delivery balloon intended to treat coronary artery disease by delivering sirolimus to blood vessels.

See Also

Analyst Recommendations for Orchestra BioMed (NASDAQ:OBIO)

Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.